TIDMCLL

RNS Number : 5462B

Cello Health PLC

21 September 2018

21 September 2018

Cello Health plc

("Cello" or the "Group")

Director/PDMR Shareholding

The Group provides the following notification in accordance with Article 19(3) of the Market Abuse Regulation:

 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                    Alasdair Combe 
      --------------------------------------  ---------------------------------------------- 
 2     Reason for the notification 
      -------------------------------------------------------------------------------------- 
 a)    Position/status                         Person closely associated with Jane 
                                                Shirley, Joint CEO of Cello Health 
                                                Insight and CEO of Cello Health Europe 
      --------------------------------------  ---------------------------------------------- 
 b)    Initial notification                    Initial notification 
        /Amendment 
      --------------------------------------  ---------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      -------------------------------------------------------------------------------------- 
 a)    Name                                    Cello Health plc 
      --------------------------------------  ---------------------------------------------- 
 b)    LEI                                     2138004TZYGZLWQP7N64 
      --------------------------------------  ---------------------------------------------- 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      -------------------------------------------------------------------------------------- 
 a)    Description of the                      Ordinary shares of 10 pence each 
        financial instrument, 
        type of instrument 
       Identification code                     ISIN: GB00B0310763 
      --------------------------------------  ---------------------------------------------- 
 b)    Nature of the transaction               Purchase of ordinary shares 
      --------------------------------------  ---------------------------------------------- 
 c)    Price(s) and volume(s) 
                                               ---------------------  -------------------- 
                                                Price(s)               Volume(s) 
                                               ---------------------  -------------------- 
    GBP1.3487                                                          10,000 
   -----------------------------------------------------------------  -------------------- 
 
 d)    Aggregated information 
  - Aggregated volume                     10,000 
  - Price                                 GBP13,487.00 
 --------------------------------------  --------------------------------------------------- 
 e)    Date of the transaction                 20 September 2018 
      --------------------------------------  ---------------------------------------------- 
 f)    Place of the transaction                AIMX 
      --------------------------------------  ----------------------------------------------

Enquiries:

 
 Cello Health plc                  020 7812 8460 
 Mark Scott, Chief Executive 
 Mark Bentley, Finance Director 
 
 Cenkos Securities plc             0207 397 8900 
 Mark Connelly 
  Harry Hargreaves

Notes to Editors

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise, differentiate their assets, and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.

For further information, please visit: https://cellohealthplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHFKDDKCBKKFCB

(END) Dow Jones Newswires

September 21, 2018 05:15 ET (09:15 GMT)

Cello Health (LSE:CLL)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Cello Health Charts.
Cello Health (LSE:CLL)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Cello Health Charts.